Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Great turnout for Hannes Meyer Symposium in Cardiothoracic Surgery
2017-05-05

Description: Hannes Meyer Symposium  Tags: Hannes Meyer Symposium

Symposium attendees watch attentively as
Dr Johan Brink demonstrated a MAZE procedure
with a pig’s heart.
Photo: Supplied

The University of the Free State’s Faculty of Health Sciences hosted the annual Hannes Meyer Symposium in Cardiothoracic Surgery. The symposium was organised by Prof Francis Smit, head of the department of Cardiothoracic Surgery at the UFS, with the support from the Society of Cardiothoracic Surgeons of South Africa and the European Association of Cardiothoracic Surgery (EACTS). Over the past 16 years this symposium has steadily been growing in stature and prestige leading to the resounding success that was this year’s event.

Medical advancements explored
The aim of the symposium is to provide an overview of the latest advances in Cardiothoracic Surgery and perfusion as well as providing hands-on training via simulation to trainees from South Africa and the rest of the African continent. Didactic lectures and papers by registrars were an integral component of the symposium. The South African community was represented by various heads of departments, trainees, senior specialists and perfusionists from all the training centres in the country. There were also delegates representing Uganda, Mozambique, Nigeria and Zambia.

Heart surgery off to new heights
Simulation in Cardiothoracic Surgery and Perfusion can be compared to airline pilots with high risk, with complex surgeries being first done in simulators before being attempted in the real world. The UFS is proud to have a state-of-the-art simulation facility, which was used to facilitate the programme.

The range of simulation was extensive and included simple procedural models to complex full theatre setups with Human Performance Models in perfusion that simulated crisis scenarios with the aid of computerised devices that react in real time to human intervention.

Industry support highly appreciated
This event was coordinated by Dr Jehron Pillay, senior registrar in the Department of Cardiothoracic Surgery and Marilee Janse van Vuuren, deputy-director clinical technology, in the department. This was the first time that such extensive simulation models were used in the programme and judging from the positive response received, it has certainly set the benchmark for all future events.

The event has received invaluable support over the years from EACTS that has selected Bloemfontein as the site of its African training programme as a result of the high level of training and education achieved here.

The academic discussions were chaired by Profs Marko Turina and Jose Pomar (past presidents of EACTS) and Pieter Kappetein (past secretary general of EACTS) who are extremely well known internationally for their contribution to advancing Cardiothoracic training and education.

Our guests from EACTS presented didactical lectures on research methodology, international randomised trials and discussed recent developments and controversies in cardiothoracic surgery.

Registrars from all South African units presented a thoracic and cardiac surgery paper from each unit highlighting specific disease conditions, moderated by heads of departments and the international panel.

An event of this magnitude requires significant financial support and the medical industry in South Africa stepped up to the plate in providing financial and logistical support in order to make it possible.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept